Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Regorafenib · 1 trial · 1 indication
time from randomization to the date of death due to any cause. For patients still alive at the time of analysis, the OS time will be censored on the last date the patients were known to be alive.
| Arm | Type | Description |
|---|---|---|
| Panitumumab followed by Regorafenib | ACTIVE_COMPARATOR | - |
| Regorafenib followed by Panitumumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Regorafenib | DRUG | regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics: 1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept); 2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment; 3. RAS and BRAF wt ct-DNA at the time of screening. |
| Panitumumab | DRUG | panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics: 1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept); 2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment; 3. RAS and BRAF wt ct-DNA at the time of screening. |
Inclusion Criteria: * Age ≥ 18 years. * Written informed consent to molecular analyses. * Histologically proven diagnosis of CRC. * At least one measurable lesion according to RECIST1.1 * ECOG PS ≤ 1. * mCRC previously treated for metastatic disease with, or not considered candidates for, fluoropyr...
Top 20 of 79 competitors
Regorafenib is an investigational small molecule being studied for the treatment of Colorectal Cancer. It is currently in Phase 2 clinical development. The drug is being evaluated in a clinical trial involving patients with this condition.
Regorafenib is a kinase inhibitor that targets multiple proteins, including DDR2, EPHA2, FGFR2, MAPK11, PDGFRB, PDGFRA, BRAF, KIT, TEK, FGFR1, NTRK1, RAF1, ABL1, FRK, RET, FLT1, FLT4, and KDR. By inhibiting these targets, it may interfere with cancer cell growth and survival.
Regorafenib is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker AMGN. The drug is currently in Phase 2 clinical development for Colorectal Cancer.
Regorafenib is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing trial is active but not recruiting participants, with a planned enrollment of 214 patients.
Regorafenib is being studied in a Phase 2 clinical trial with the identifier NCT04787341. The trial is titled "PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence" and is being conducted in Italy. It enrolls adults aged 18 years and older with Colorectal Cancer.
Regorafenib is also known by the ChEMBL identifier CHEMBL1946170. This identifier is used in chemical databases to reference the compound. The drug is being investigated under this name in research and clinical contexts.